Linezolid Sandoz (Linezolid)

Linezolid is indicated for several serious bacterial infections, particularly those caused by resistant Gram‑positive organisms.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective therapy for skin, bloodstream and respiratory infections caused by MRSA.
• Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative treatment option for VRE bloodstream and intra‑abdominal infections.
• Community‑acquired pneumonia: used to treat adult patients with pneumonia caused by susceptible Streptococcus pneumoniae or other Gram‑positive pathogens.
• Skin and soft‑tissue infections: indicated for complicated cellulitis, abscesses and wound infections caused by susceptible organisms.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex and thereby blocking translation. This action is bacteriostatic against most susceptible strains and bactericidal at higher concentrations, targeting Gram‑positive organisms including MRSA and VRE. The binding site is distinct from those of other antibiotic classes, which reduces cross‑resistance.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste sensation.
• Myelosuppression (thrombocytopenia, anemia): reversible reduction in blood cell counts.
• Rash: mild skin eruption.

Serious or Rare Side Effects

• Serotonin syndrome: risk when combined with serotonergic agents.
• Peripheral neuropathy: sensory changes with prolonged use.
• Lactic acidosis: metabolic disturbance, rare but severe.
• Vision changes: optic neuropathy leading to visual loss.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing Linezolid, clinicians should consider several safety and handling precautions.

• Monitor blood counts: regular CBCs to detect thrombocytopenia or anemia.
• Assess renal and hepatic function: dose adjustment may be needed in severe impairment.
• Avoid serotonergic drugs: risk of serotonin syndrome when combined with SSRIs, MAO inhibitors, or linezolid.
• Limit duration of therapy: prolonged use increases risk of neuropathy and myelosuppression.
• Use with caution in pregnancy: safety data are limited; weigh benefits against potential risks.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Linezolid has notable drug interaction potential that requires careful management.

Major Interactions (Avoid)

• SSRIs, SNRIs, MAO inhibitors, tricyclic antidepressants: may precipitate serotonin syndrome.
• Rifampicin: induces hepatic enzymes, reducing linezolid plasma concentrations.
• Tyramine‑rich foods: can cause hypertensive reactions when combined with linezolid’s MAO‑inhibiting effect.

Moderate Interactions (Monitor Closely)

• Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring.
• Cyclosporine and tacrolimus: may increase levels, necessitate dose adjustment.
• Ethanol: potential for disulfiram‑like reaction, monitor for flushing.